Substance P in rheumatic diseases

Current Rheumatology Reviews

Volumn 3, Issue 1, 2007, Pages 17-30

  Seidel, Matthias F ^a   Tsalik, Julia ^b   Vetter, Hans ^a   Müller, Wolfgang ^c  

^a Medizinische Universitäts Poliklink Rheumatology ^*  (Germany)

^b Krankenhaus Bethanien   (Germany)

^c Hochrhein Institut für Rheumaforschung   (Germany)

Author keywords

Neurogenic inflammation; Review; Rheumatic diseases; Substance P

Indexed keywords

2 BENZYL 1 (3,5 DIMETHYLBENZOYL) 4 (4 QUINOLINYLMETHYLAMINO)PIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; ADENOSINE; AMITRIPTYLINE; APREPITANT; CAPSAICIN; CARBAMAZEPINE; CISPLATIN; GLYCERYL TRINITRATE; IBUPROFEN; L 7540303; LY 303875; NEUROKININ 1 RECEPTOR ANTAGONIST; NOLPITANTIUM; OPIATE; SDZNKT 34311; SEROTONIN UPTAKE INHIBITOR; SOMATOSTATIN; SUBSTANCE P; UNCLASSIFIED DRUG; VOFOPITANT;

ANTIEMETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; AUTOIMMUNE DISEASE; AXOPLASM FLOW; BRAIN ISCHEMIA; CHEMOTHERAPY INDUCED EMESIS; CHRONIC FATIGUE SYNDROME; COLITIS; COMPLEX REGIONAL PAIN SYNDROME TYPE I; DEGENERATIVE DISEASE; DOWN REGULATION; DRUG EFFICACY; FIBROMYALGIA; GENE OVEREXPRESSION; GOUT; HUMAN; IMMUNOMODULATION; INFLAMMATION; NERVOUS SYSTEM; NEUROGENIC INFLAMMATION; NEUROPATHIC PAIN; NOCICEPTIVE RECEPTOR; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN TRANSPORT; PSORIATIC ARTHRITIS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCLERODERMA; SJOEGREN SYNDROME; SPINE DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VASCULITIS;

EID: 34247189685     PISSN: 15733971     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339707779815830     Document Type: Review

References (192)

1. Pattrick M, Doherty M, Dieppe P. Unilateral exacerbation of rheumatoid arthritis by hemiparesis. Br J Rheumatol 1984; 23(2): 107-9.
2. Pittock SJ. Unilateral osteoarthritis-"the working hand". N Engl J Med 2002; 346(10): e3.
3. Courtright LJ, Kuzell WC. Sparing effect of neurological deficit and trauma on the course of adjuvant arthritis in the rat. Ann Rheum Dis 1965; 24(4): 360-8.
4. Jancso N, Jancso-Gabor A, Scolcsanyi. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol 1967; 31: 138-51.
5. Mossner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun 1998; 12(4): 249-71.
6. Berczi I, Chalmers IM, Nagy E, Warrington RJ. The immune effects of neuropeptides. Baillieres Clin Rheumatol 1996; 10(2): 227-57.
7. Herbert MK, Holzer P. Why are substance P(NK1)-receptor antagonists ineffective in pain treatment? Anaesthesist 2002; 51(4): 308-19.
8. Ren K, Dubner R. Central nervous system plasticity and persistent pain. J Orofac Pain 1999; 13(3): 155-63.
9. Riedel W, Neeck G. Nociception, pain, and antinociception: current concepts. Z Rheumatol 2001; 60(6): 404-15.
10. Gibson SJ, Polak JM, Bloom SR, et al. Calcitonin gene-related peptide immunoreactivity in the spinal cord of man and of eight other species. J Neurosi 1984; 4(12): 3101-11.
11. Moller K, Zhang YZ, Hakanson R, et al. Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence. Neuroscience 1993; 57(3): 725-32.
12. Holzer P. Peptidergic sensory neurons in the control of vascular functions: mechanism and significance in the cutaneous and splanchnic vascular beds. Rev Physiol Biochem Pharmacol 1992; 121: 49-146.
13. Bayliss WM. On the origin of the spinal cord of the vaso-dilator fibres of the hind-limb and on the nature of these fibres. J Physiol (Lond) 1901; 26: 173-209.
14. Lewis T. Experiments relating to cutaneous hyperalgesia and its spread through somatic nerves. Clin Sci 1936; 2: 373-423.
15. Willis WD Jr. Dorsal root potentials and dorsal root reflexes: a double-edged sword. Exp Brain Res 1999; 124(4): 395-421.
16. Lin Q, Wu J, Willis WD. Dorsal root reflexes and cutaneous neurogenic inflammation after intradermal injection of capsaicin in rats. J Neurophysiol 1999; 82(5): 2602-11.
17. Maggi CA, Abelli L, Giuliani S, et al. The contribution of sensory nerves to xylene-induced cystitis in rats. Neuroscience 1988; 26(2): 709-23.
18. McGillis JP, Mitsuhashi M, Payan DG. Immunomodulation by tachykinin neuropeptides. Ann N Y Acad Sci 1990; 594: 85-94.
19. Khawaja AM, Rogers DF. Tachykinins: receptor to effector. Int J Biochem Cell Biol 1996; 28(7): 721-38.
20. Watling KJ, Guard S, Krause JE, et al. On the presence of NK2 receptor subtypes in peripheral and central tissues. Regul Pept 1993; 46(1-2): 311-3.
21. Gerard NP, Bao L, Xiao-Ping H, Gerard C. Molecular aspects of the tachykinin receptors. Regul Pept 1993; 43(1-2): 21-35.
22. Nakanishi S. Mammalian tachykinin receptors. Annu Rev Neurosci 1991; 14: 123-36.
23. Regoli D, Boudon A. Fauchere J. Receptors and antagonists for substance P and related peptides. Pharmacol Rev 1994; 46(4):551-99.
24. Jeurissen F, Kavelaars A, Korstjens M, et al. Monocytes express a non-neurokinin substance P receptor that is functionally coupled to MAP-kinase. J Immunol. 1994; 152(6): 2987-94.
25. Von Euler US, Gaddum JH. An unidentified depressor substance in certain tissue extracts. J Physiol 1931; 72: 74-87.
26. Lembeck F. Central transmission of afferent impulses. III. Incidence and significance of the substance P in the dorsal roots of the spinal cord. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 1953; 219(3): 197-213.
27. Pernow B. Substance P. Pharmacol Rev 1983; 35(2): 85-141.
28. Foreman JC. Peptides and neurogenic inflammation. Br Med Bull 1987; 43(2): 386-400.
29. Datar P, Srivastava S, Coutinho E, Govil G. Substance P: structure, function, and therapeutics. Curr Top Med Chem 2004; 4(1): 75-103.
30. Harrison S, Geppetti P. Substance p. Int J Biochem Cell Biol 2001 Jun 33(6): 555-76.
31. Barker PA, Hussain NK, McPherson PS. Retrograde signaling by the neurotrophins follows a well-worn trk. Trends Neurosci 2002; 25(8): 379-81.
32. Shults CW, Quirion R, Chronwall B, Chase TN, O'Donohue TL. A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system. Peptides 1984; 5(6): 1097-128.
33. Lee Y, Kawai Y, Shiosaka S, et al. Coexistence of calcitonin generelated peptide and substance P-like peptide in single cells of the trigeminal ganglion of the rat: immunohistochemical analysis. Brain Res 1985; 330(1): 194-6.
34. Gibbins IL, Wattchow D, Coventry B. Two immunohistochemically identified populations of calcitonin gene-related peptide (CGRP)-immunoreactive axons in human skin. Brain Res 1987; 414(1): 143-8.
35. Sternini C, Su D, Gamp PD, Bunnett NW. Cellular sites of expression of the neurokinin-1 receptor in the rat gastrointestinal tract. J Comp Neurol 1995; 358(4): 531-40.
36. Rosenfeld MG, Mermod JJ, Amara SG, et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 1983; 304(5922): 129-35.
37. Brain SD. Sensory neuropeptides: their role in inflammation and wound healing. Immunopharmacology 1997; 37(2-3): 133-52.
38. Bjorklund H, Dalsgaard CJ, Jonsson CE, Hermansson A. Sensory and autonomic innervation of non-hairy and hairy human skin. An immunohistochemical study. Cell Tissue Res 1986; 243(1): 51-7.
39. Bjurholm A, Kreicbergs A, Brodin E, Schultzberg M. Substance P- and CGRP-immunoreactive nerves in bone. Peptides 1988; 9(1): 165-71.
40. Messlinger K, Hanesch U, Kurosawa M, Pawlak M, Schmidt RF. Calcitonin gene related peptide released from dural nerve fibers mediates increase of meningeal blood flow in the rat. Can J Physiol Pharmacol 1995; 73(7): 10204.
41. Uddman R, Edvinsson L, Ekblad E, Hakanson R, Sundler F. Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept 1986; 15(1): 1-23.
42. Brain SD, Williams TJ, Tipins JR, Morris HR, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985; 313: 54-56.
43. Zaidi M, Bevis PJR, Girgis SI, Lynch C, Stevenson JC, MacIntyre I. Circulating CGRP comes from the perivascular nerves. Eur J Pharmacol 1985; 117: 283-4.
44. Ralevic V, Khalil Z, Dusting GJ, Helme RD. Nitric oxide and sensory nerves are involved in the vasodilator response to acetylcholine but not calcitonin gene-related peptide in rat skin microvasculature. Br J Pharmacol 1992; 106(3): 650-5.
45. Pedersen-Bjergaard U, Nielsen LB, Jensen K, Edvinsson L, Jansen I, Olesen J. Calcitonin gene-related peptide, neurokinin A and substance P: effects on nociception and neurogenic inflammation in human skin and temporal muscle. Peptides 1991; 12(2): 333.
46. Berczi I, Chalmers IM, Nagy E, Warrington RJ. The immune effects of neuropeptides. Baillieres Clin Rheumatol 1996; 10(2): 227-57.
47. Weihe E, Nohr D, Michel S, et al. Int J Neurosci 1991; 59(1-3): 1-23.
48. Serra MC, Bazzoni F, Della Bianca V, Greskowiak M, Rossi F. Activation of human neutrophils by substance P. Effect on oxidative metabolism, exocytosis, cytosolic Ca2+ concentration and inositol phosphate formation. J Immunol 1988; 141(6):2118-24.
49. Jeurissen F. Kavelaars A, Korstjens M, et al. Monocytes express a non-neurokinin substance P receptor that is functionally coupled to MAP-kinase. J Immunol 1994; 152(6): 2987-94.
50. Ruff MR, Wahl SM, Pert CB. Substance P receptor-mediated chemotaxis of human monocytes. Peptides 1985; 6 (Suppl. 2): 107-111.
51. Hartung HP, Toyka, KV. Activation of macrophages by substance P: induction of oxidative burst and thromboxane release. Eur J Pharmacol 1983; 89(3-4): 301-5.
52. Lotz M, Carson DA, Vaughan JH. Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science 1987; 235(4791): 893-5.
53. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. Science 1988; 241(4870): 1218-21.
54. Hafstrom I, Gyllenhammar H, Palmblad J, Ringertz B. Substance P activates and modulates neutrophil oxidative metabolism and aggregation. J Rheumatol 1989; 16(8): 1033-7.
55. Tominaga K, Honda K, Akahoshi A, et al. Substance P causes adhesion of neutrophils to endothelial cells via protein kinase C. Biol Pharm Bull 1999; 22(11): 1242-5.
56. Nakagawa N, Sano H, Iwamoto I. Substance P induces the expression of intercellular adhesion molecule-1 on vascular endothelial cells and enhances neutrophil ransendothelial migration. Peptides 1995; 16(4): 721-5.
57. Serra MC, Calzetti F, Ceska M, Cassatella MA. Effect of substance P on superoxide anion and IL-8 production by human PMNL. Immunology 1994; 82(1): 63-9.
58. Payan DG, Brewster DR, Goetzl EJ. Stereospecific receptors for substance P on cultured human IM-9 lymphoblasts. J Immunol 1984; 133(6): 3260-5.
59. Payan DG, Brewster DR, Goetzl EJ. Specific stimulation of human T lymphocytes by substance P. J Immunol 1983; 131(4): 1613-5.
60. Feistritzer C, Clausen J, Sturn DH, et al. Natural killer cell functions mediated by the neuropeptide substance P. Regul Pept 2003; 116(1-3): 119-26.
61. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides 1997; 31(6): 537-63.
62. Campbell EA. Gentry CT, Patel S. Panesar MS, Walpole CS, Urban L. Selective neurokinin-1 receptor antagonists are antihyperalgesic in a model of neuropathic pain in the guinea-pig. Neuroscience 1998; 87(3): 527-32.
63. File SE. Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test. Pharmacol Biochem Behav 1997; 58(3): 747-52.
64. Di Sebastiano P, Grossi L, Di Mola FF, et al. SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis. Dig Dis Sci 1999; 44(2): 439-44.
65. Yu Z, Cheng G, Huang Y, Li K, Cao X. Neurokinin-1 receptor antagonist SR140333: a novel type of drug to treat cerebral ischemia. Neuroreport 1997; 8(9-10): 2117-9.
66. Gardner CJ, Armour DR, Beattie DT, et al. GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept 1996; 65(1): 45-53.
67. Tattersall FD, Rycroft W, Cumberbatch M, et al. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 2000; 39(4): 652-63.
68. Binder W, Scott C, Walker JS. Involvement of substance P in the anti-inflammatory effects of the peripherally selective kappa-opioid asimadoline and the NK1 antagonist GR205171. Eur J Neurosci 1999; 11(6): 2065-72.
69. Dionne RA, Max MB, Gordon SM, et al. The substance P receptor antagonist CP-99,994 reduces acute postoperative pain. Clin Pharmacol Ther 1998; 64(5): 562-8.
70. Navari RM, Reinhardt RR, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med 1999; 340(3): 190-5.
71. Craft RM, Porreca F. Treatment parameters of desensitization to capsaicin. Life Sci 1992; 51(23): 1767-75.
72. Rains C, Bryson HM. Topical capsaicin. A review of its pharmacological properties and therapeutic potential in post-herpetic neuralgia, diabetic neuropathy and osteoarthritis. Drugs Aging 1995; 7(4): 317-28.
73. Nagy JI, Iversen LL, Goedert M, Chapman D, Hunt SP. Dose-dependent effects of capsaicin on primary sensory neurons in the neonatal rat. J Neurosi 1983; 3(2): 399-406.
74. Jancso G, Kiraly E, Joo F, Such G, Nagy A. Selective degeneration by capsaicin of a subpopulation of primary sensory neurons in the adult rat. Neurosci Lett 1985; 59(2): 209-14.
75. Buck SH, Burks TF. The neuropharmacology of capsaicin: review of some recent observations. Pharmacol Rev 1986; 38(3): 179-226.
76. Winter S. Unilateral heberden's nodes in a case of hemiplegia. N Y State J Med 1952; 52(3): 349-50.
77. Jacqueline F. A case of evolutive polyarthritis with localisation controlateral to a hemiplegia. Rev Rhum Mal Osteoartic 1953; 20(4): 323-4.
78. Thompson M, Bywaters EG. Unilateral rheumatoid arthritis following hemiplegia. Ann Rheum Dis 1962; 21: 370-7.
79. Glynn JJ, Clayton ML. Sparing effect of hemiplegia on tophaceous gout. Ann Rheum Dis 1976; 35(6): 534-5.
80. Fontanet A, Menkes CJ. Hemiplegia and contralateral multiple joint disease caused by chondrocalcinosis. Rev Rhum Mal Osteoartic 1989; 56(11): 789-90.
81. Glick EN. Asymmetrical rheumatoid arthritis after poliomyelitis. Br Med J 1967; 3(556): 26-8.
82. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 1996; 39(11): 1781-90.
83. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 1999; 26(3): 717-9.
84. Lambert N, Lescoulie PL, Yassine-Diab B, Enault G, Mazieres B, De Preval C, Cantagrel A. Substance P enhances cytokine-induced vascular cell adhesion molecule-1 (VCAM-1) expression on cultured rheumatoid fibroblast-like synoviocytes. Clin Exp Immunol. 1998; 113(2): 269-75.
85. Krause JE, DiMaggio DA, McCarson KE. Alterations in neurokinin 1 receptor gene expression in models of pain and inflammation. Can J Physiol Pharmacol 1995; 73(7): 854-9.
86. Sowers M, Jannausch M, Stein E, Jamadar D, Hochberg M, Lachance L. C-reactive protein as a biomarker of emergent osteoarthritis. Osteoarthritis Cartilage 2002; 10(8): 595-601.
87. Gronblad M, Konttinen YT, Korkala O, Liesi P, Hukkanen M, Polak JM. Neuropeptides in synovium of patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 1988; 15(12): 1807-10.
88. Mapp PI, Kidd BL, Gibson SJ, et al. Substance P-, calcitonin gene-related peptide- and C-flanking peptide of neuropeptide Y-immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis. Neuroscience 1990; 37(1): 143-53.
89. Miller LE, Justen HP, Scholmerich J, Straub RH. The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages. FASEB J 2000, 14(13): 2097-107. Errattum in: FASEB J. 2001; 15(13): 2554.
90. Saito T, Koshino T. Distribution of neuropeptides in synovium of the knee with osteoarthritis. Clin Orthop 2000; (376): 172-82.
91. Inoue H, Shimoyama Y, Hirabayashi K, et al. Production of neuropeptide substance P by synovial fibroblasts from patients with rheumatoid arthritis and osteoarthritis. Neurosci Lett 2001; 303(3): 149-52.
92. Partsch G, Matucci-Cerinic M, Marabini S, Jantsch S, Pignone A, Cagnoni M, Collagenase synthesis of rheumatoid arthritis synoviocytes: dose-dependent stimulation by substance P and capsaicin. Scand J Rheumatol 1991; 20(2): 98-103.
93. Brunelleschi S, Bordin G, Colangelo D, Viano I. Tachykinin receptors on human monocytes: their involvement in rheumatoid arthritis. Neuropeptides 1998; 32(3): 215-23.
94. O'Byrne EM, Blancuzzi V, Wilson DE, Wong M, Jeng AY. Elevated substance P and accelerated cartilage degradation in rabbit knees injected with interleukin-1 and tumor necrosis factor. Arthritis Rheum 1990; 33(7): 1023-8.
95. Covas MJ, Pinto LA, Pereira Da Silva JA, Victorino RM. Effects of the neuropeptide, substance P, on lymphocyte proliferation in rheumatoid arthritis. J Int Med Res 1995; 23(6): 431-8.
96. Anichini M, Cesaretti S, Lepori M, Maddali Bongi S, Maresca M, Zoppi M. Substance P in the serum of patients with rheumatoid arthritis. Rev Rhum Engl Ed 1997; 64(1): 18-21.
97. Larsson J, Ekblom A, Henriksson K, Lundeberg T, Theodorsson E. Immunoreactive tachykinins, calcitonin gene-related peptide and neuropeptide Y in human synovial fluid from inflamed knee joints. Neurosci Lett 1989; 100(1-3): 326-30.
98. Larsson J, Ekblom A, Henriksson K, Lundeberg T, Theodorsson E. Concentration of substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol 1991; 20(5): 326-35.
99. Marshall KW, Chiu B, Inman RD. Substance P and arthritis: analysis of plasma and synovial fluid levels. Arthritis Rheum 1990; 33(1): 87-90.
100. Matucci-Cerinic M, Partsch G, Marabini S, Cagnoni M. High levels of substance P in rheumatoid arthritis synovial fluid. Lack of substance P production by synoviocytes in vitro. Clin Exp Rheumatol 1991; 9(4): 440-1.
101. Matucci-Cerinic M, Lombardi A, Leoncini G, Pignone A, Sacerdoti L, Spillantini MG, Partsch G. Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation? Rheumatol Int 1993; 13(1): 1-4.
102. Marabini S, Matucci-Cerinic M, Geppetti P, et al. Substance P and somatostatin levels in rheumatoid arthritis, osteoarthritis, and psoriatic arthritis synovial fluid. Ann N Y Acad Sci 1991; 632: 435-6.
103. Hernanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon J, Arnalich F. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol 1993; 32(1): 31-5.
104. Menkes CJ, Renoux M, Laoussadi S, Mauborgne A, Bruxelle J, Cesselin F. Substance P levels in the synovium and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 1993; 20(4): 714-7.
105. Agro A, Stanisz AM. Are lymphocytes a target for substance P modulation in arthritis? Semin Arthritis Rheum 1992; 21(4): 252-8.
106. Lindh C, Liu Z, Lyrenas S, Ordeberg G, Nyberg F. Elevated cerebrospinal fluid substance P-like immunoreactivity in patients with painful osteoarthritis, but not in patients with rhizopatic pain from a herniated lumbar disc. Scand J Rheumatol 1997; 26(6): 468-72.
107. Devillier P, Weill B, Renoux M, Menkes C, Pradelles P. Elevated levels of tachykinin-like immunoreactivity in joint fluids from patients with rheumatic inflammatory diseases. N Engl J Med 1986; 314(20): 1323.
108. Westermark T, Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Kjorell U, Forsgren S. Increased content of bombesin/GRP in human synovial fluid in early arthritis: different pattern compared with substance P. Clin Exp Rheumatol 2001; 19(6): 715-20.
109. Marabini S, Matucci-Cerinic M, Geppetti P, et al. Substance P and somatostatin levels in rheumatoid arthritis, osteoarthritis, and psoriatic arthritis synovial fluid. Ann N Y Acad Sci 1991; 632: 435-6.
110. Lunam CA, Gentle MJ. Substance P immunoreactive nerve fibres in the domestic chick ankle joint before and after acute urate arthritis. Neurosci Lett 2004; 354(2): 87-90.
111. Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs 2000; 9(7): 1511-22.
112. Costello PJ, Winchester RJ, Curran SA, et al. Psoriatic arthritis joint fluids are characterized by CD8 and CD4 T cell clonal expansions appear antigen driven. J Immunol 2001; 166(4): 2878-86.
113. Laloux L, Voisin MC, Allain J, et al. Immunohistological study of entheses in spondyloarthropathics: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001; 60(4): 316-21.
114. Punzi L, Pianon M, Bertazzolo N, et al. Clinical, laboratory and immunogenetic aspects of post-traumatic psoriatic arthritis: a study of 25 patients. Clin Exp Rheumatol 1998; 16(3): 277-81.
115. Langevitz P, Buskila D, Gladman DD. Psoriatic arthritis precipitated by physical trauma. J Rheumatol 1990; 17(5): 695-7.
116. Thomachot B, Lafforgue P, Acquaviva PC. [Post-traumatic psoriatic arthritis. 2 cases]. Presse Med 1996; 25(1): 21-4.
117. Vasey FB. Etiology and pathogenesis of psoriatic arthritis. In: Gerber LH, Espinoza LR, eds. Psoriatic Arthritis. Grune and Stratton, 1985: 45-57.
118. Fearon U, Veale DJ. Pathogenesis of psoriatic arthritis. Clin Exp Dermatol 2001; 26(4): 333-7.
119. Weiner SR, Bassett LW, Reichman RP. Protective effect of poliomyelitis on psoriatic arthritis. Arthritis Rheum 1985; 28(6): 703-6.
120. Veale D, Farrell M, Fitzgerald O. Mechanism of joint sparing in a patient with unilateral psoriatic arthritis and a longstanding hemiplegia. Br J Rheumatol 1993; 32(5): 413-6.
121. Mulherin D, Bresnihan B, FitzGerald O. Digital denervation associated with absence of nail and distal interphalangeal joint involvement in psoriatic arthritis. J Rheumatol 1995; 22(6): 1211-2.
122. Partridge REH, Duthie JJR. Controlled trial of the effect of complete immobilization of the joints in rheumatoid arthritis. Ann Rheum Dis 1963; 22: 91-9.
123. Bracci-Laudiero L, Aloe L, Stenfors C, Theodorsson E, Lundeberg T. Development of systemic lupus erythematosus in mice is associated with alteration of neuropeptide concentrations in inflamed kidneys and immunoregulatory organs. Neurosci Lett 1998; 248(2): 97-100.
124. Bracci-Laudiero L, Aloe L, Lundeberg T, Theodorason E, Stenfors C. Altered levels of neuropeptides characterize the brain of lupus prone mice. Neurosci Lett 1999; 275(1): 57-60.
125. Huston JP, Hasenohrl RU. The role of neuropeptides in learning: focus on the neurokinin substance P. Behav Brain Res 1995; 66(1-2): 117-27.
126. Tobin D, Nabarro G, Baart de la Faille H, van Vloten WA, van der Putte SC, Schuurman HJ. Increased number of immunoreactive nerve fibers in atopic dermatitis. J Allergy Clin Immunol 1992; 90(4 Pt 1): 613-22.
127. Haustein UF, Weber B, Seikowski K. Substance P and vasoactive intestinal peptide in patients with progressive scleroderma. Determination of plasma level before and after autogenic training. Hautarzt 1995; 46(2): 102-6.
128. Wallengren J, Akesson A, Scheja A, Sundler F. Occurrence and distribution of peptidergic nerve fibers in skin biopsies from patients with systemic sclerosis. Acta Derm Venereol 1996; 76(2): 126-8.
129. Matucci-Cerinic M, Pietrini U, Marabini S. Local venomotor response to intravenous infusion of substance P and glyceryl trinitrate in systemic sclerosis. Clin Exp Rheumatol 1990; 8(6): 561-5.
130. Bunker CB, Foreman JC, Dowd PM. Digital cutaneous vascular responses to histamine and neuropeptides in Raynaud's phenomenon. J Invest Dermatol 1991; 96(3): 314-7.
131. Freedman RR, Girgis R, Mayes MD. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. J Rheumatol 2001; 28(1): 119-21.
132. Cailes J, Winter S, du Bois RM, Evans TW. Defective endothelially mediated pulmonary vasodilation in systemic sclerosis. Chest 1998; 114(1): 178-84.
133. Matucci-Cerinic M. Sensory neuropeptides and rheumatic diseases. Rheum Dis Clin N Am 1993; 19(4): 975-91.
134. Mandahl A, Bill A. Ocular responses to antidromic trigeminal stimulation, intracameral prostaglandin E1 and E2, capsaicin and substance P. Acta Physiol Scand 1981; 112(3): 331-8.
135. Del Rosso A, Bertinotti L, Pietrini U, et al. Pupillocynetic activity of substance P in systemic sclerosis. J Rheumatol 2003; 30(6): 1231-7.
136. Bathayar B, Feher E, Nagy G, Zelles T. [Changes of the nerve fibers innervating the minor salivary glands in Sjogren syndrome]. Orv Hetil 2002; 143(26): 1585-8.
137. Ekström J, Ukman R, Hakanson R, Sjogren S, Sundler F. Calcitonin gene-related peptide in rat salivary glands: neuronal localization, depletion upon nerve stimulation, and effects on salivation in relation to substance P. Neuroscience 1988; 26(3): 933-49.
138. Feher E, Zelles T, Nagy G. Immunocytochemical localisation of neuropeptide-containing nerve fibres in human labial glands. Arch Oral Biol 1999; 44 (Suppl. 1): S33-7.
139. Batbayar B, Nagy G, Kovesi G, Zelles T, Feher E. Morphological basis of sensory neuropathy and neuroimmunomodulation in minor salivary glands of patients with Sjsögren's syndrome. Arch Oral Biol 2004; 49(7): 529-38.
140. Pedersen AM, Dissing S, Fahrenkrug J, Hannibal J, Reibel J, Nauntofte B. Innervation pattern and Ca2+ signalling in labial salivary glands of healthy individuals and patients with primary Sjogren's syndrome (pSS). J Oral Pathol Med 2000; 29(3): 97-109.
141. Konttinen YT, Hukkanen M, Kemppinen P, et al. Peptide-containing nerves in labial salivary glands in Sjogren's syndrome. Arthritis Rheum 1992; 35(7): 815-20.
142. Konttinen YT, Tornwall J, Kemppinen P, et al. Neutral endopeptidase (EC 3.4.24.11) in labial salivary glands in healthy controls and in patients with Sjogren's syndrome. Ann Rheum Dis 1996; 55(8): 513-9.
143. Calder JS, Holten I, McAllister RM. Evidence for immune system involvement in reflex sympathetic dystrophy. J Hand Surg [Br] 1998; 23(2): 147-50.
144. Cheshire WP, Snyder CR. Treatment of reflex sympathetic dystrophy with topical capsaicin. Case report. Pain 1990; 42(3): 307-11.
145. Denko CW, Gabriel P. Effects of peptide hormones in urate crystal inflammation. J Rheumatol 1985; 12(5): 971-5.
146. Littlejohn GO, Weinstein C, Helme RD. Increased neurogenic inflammation in fibrositis syndrome. J Rheumatol 1987; 14(5): 1022-5.
147. Eneström S, Bengtsson A, Frodin T. Dermal IgG deposits and increase of mast cells in patients with fibromyalgia - relevant findings or epiphenomena? Scand J Rheumatol 1997; 26(4): 308-13.
148. Vaeroy H, Helle R, Forre O, Kass E, Terenius L. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis 1988 Jan;32(1): 21-6.
149. Bradley LA, Alberta KR, Alarcon GS, et al. Abnormal brain regional cerebral blood flow (rCBF) and cerebrospinal fluid(CSF)levels of substance P (SP) in patients and non-patients with fibromyalgia (FM). Arthritis Rheum 1996; 39 (Suppl): S212.
150. Giovengo SL, Russell IJ, Larson AA. Increased concentrations of nerve growth factor in cerebrospinal fluid of patients with fibromyalgia. J Rheumatol 1999; 26(7): 1564-9.
151. Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994; 37(11): 1593-601.
152. Evengard B, Nilsson CG, Lindh G, et al. Chronic fatigue syndrome differs from fibromyalgia. No evidence for elevated substance P levels in cerebrospinal fluid of patients with chronic fatigue syndrome. Pain 1998; 78(2): 153-5.
153. Reynolds WJ, Chiu B, Inman RD. Plasma substance P levels in fibrositis. J Rheumatol 1988; 15(12): 1802-3.
154. Samborski W, Stratz T, Schochat T, Mennet P, Muller W. [Biochemical changes in fibromyalgia]. Z Rheumatol 1996; 55(3): 168-73.
155. Sprott H, Bradley LA, Oh SJ, et al. Immunohistochemical and molecular studies of serotonin, substance P, galanin, pituitary adenylyl cyclase-activating polypeptide, and secretoneurin in fibromyalgic muscle tissue. Arthritis Rheum 1998; 41(9): 1689-94.
156. De Stefano R, Selvi E, Villanova M, et al. Image analysis quantification of substance P immunoreactivity in the trapezius muscle of patients with fibromyalgia and myofascial pain syndrome. J Rheumatol 2000; 27(12): 2906-10.
157. Späth M, Stratz Th, Schmalisch P, et al. Substance P in skeletal muscle of patients with fibromyalgia syndrom. J. Musculoskel Pain 1998; 6 (Suppl): 2.
158. Wolin M, Bragee B, Nyberg F, Kristiansson M. Elevated substance P levels are contrasted by a decrease in met-enkephalin-arg-phe levels in CSF from fibromyalgia patients. J Musculoskel Pain 1995; 3(Suppl 1): 4.
159. Beaman DN, Graziano GP, Glover RA, Wojtys EM, Chang V. Substance P innervation of lumbar spine facet joints. Spine 1993; 18(8): 1044-9.
160. Ashton IK, Roberts S, Jaffray DC, Polak JM, Eisenstein SM. Neuropeptides in the human intervertebral disc. J Orthop Res 1994; 12(2): 186-92.
161. Palmgren T, Gronblad M, Virri J, Seitsalo S, Ruuskanen M, Karaharju E. Immunohistochemical demonstration of sensory and autonomic nerve terminals in herniated lumbar disc tissue. Spine 1996; 21(11): 1301-6.
162. Imasato H, Nagata K, Hashimoto S, Komori H, Inoue A. Objective evaluation of pain in various spinal diseases: neuropeptide immunoreactivity in the cerebrospinal fluid. Spinal Cord 1997; 35(11): 757-62.
163. Sameshima K. [Substance P-like immunoreactivity in cerebrospinal fluid in lumbar disc herniation]. Nippon Seikeigeka Gakkai Zasshi 1995; 69(4): 191-7.
164. Gronblad M, Weinstein JN, Santavirta S. Immunohistochemical observations on spinal tissue innervation. A review of hypothetical mechanisms of back pain. Acta Orthop Scand 1991; 62(6): 614-22.
165. Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI. Intraneuronal substance P contributes to the severity of experimental arthritis. Science 1984; 226(4674): 547-9.
166. Binder W, Scott C, Walker JS. Involvement of substance P in the anti-inflammatory effects of the peripherally selective kappa-opioid asimadoline and the NK1 antagonist GR205171. Eur J Neurosci 1999; 11(6): 2065-72.
167. Hong SK, Han JS, Min SS, et al. Local neurokinin-1 receptor in the knee joint contributes to the induction, but not maintenance, of arthritic pain in the rat. Neurosci Lett 2002; 322(1): 21-4.
168. De Felipe C, Herrero JF, O'Brien JA, et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998; 392(6674): 394-7.
169. Cao YQ, Mantyh PW, Carlson EY, Gillespie AM, Epstein CJ, Basbaum AI. Primary afferent tachykinins are required to experience moderate to intense pain. Nature 1998; 392(6674): 390-4.
170. Littman BH, Newton FA, Russel IJ. Substance P antagonism in fibromyalgia: a trial with CJ-11974. In: Abstracts from the 9th World Congress on Pain. Seattle, WA: IASP Press 1999; 67.
171. Goldstein DJ, Wang O, Todd LE, Gitter BD, DeBrota DJ, Iyengar S. Study of the analgesic effect of lanepitant in patients with osteoarthritis pain. Clin Pharmacol Ther 2000; 67(4): 419-26.
172. Reinhardt RR, Laub JB, Fricke JR, Polis AB, Gertz BJ. Comparison of neurokinin-1 antagonist, L-745,030, to placebo, acetominophen and ibuprofen in the dental pain model. Clin Pharmacol Ther 1998; 63(2): 168.
173. Datar P, Srivastava S, Coutinho E, Govil G. Substance P: structure, function, and therapeutics. Curr Top Med Chem 2004; 4(1): 75-103.
174. Mathias BJ, Dillingham TR, Zeigler DN, Chang AS, Belandres PV. Topical capsaicin for chronic neck pain. A pilot study. Am J Phys Med Rehabil 1995; 74(1): 39-44.
175. Keitel W, Frerick H, Kuhn U, Schmidt U, Kuhlmann M, Bredehorst A. Capsicum pain plaster in chronic non-specific low back pain. Arzneimittelforschung 2001; 51(11): 896-903.
176. McCleane G. The analgesic efficacy of topical capsaicin is enhanced by glyceryl trinitrate in painful osteoarthritis: a randomized, double blind, placebo controlled study. Eur J Pain 2000; 4(4): 355-60.
177. Deal CL, Schnitzer TJ, Lipstein E, et al. Treatment of arthritis with topical capsaicin: a double-blind trial. Clin Ther 1991; 13(3): 383-95.
178. McCarthy GM, McCarty DJ. Effect of topical capsaicin in the therapy of painful osteoarthritis of the hands. J Rheumatol 1992; 19(4): 604-7.
179. De Miguel E, Arnalich F, Tato E, Vazquez JJ, Gijon-Banos J, Hernanz A. The effect of gold salts on substance P levels in rheumatoid arthritis. Neurosci Lett 1994; 174(2): 185-7.
180. Saria A, Javorsky F, Humpel C, Gamse R. 5-HT3 receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord. Neuroreport 1990; 1(2): 104-6.
181. Späth M. Was gibt es Neues in der Therapie der Fibromyalgie? Schmerz. 2003; 17(6): 437-40.
182. Seidel MF, Ulrich-Merzenich G, Fiebich B, Candelario-Jalil E, Koch FW, Vetter H. Tropisetron inhibits serotonin-induced PGE2 release from macrophage-like synovial cells in serum-free tissue culture. Scand J Rheumatol 2004; (Suppl 119): 33.
183. Fiebich BL, Akundi RS, Seidel M, et al. Expression of 5-HT3A receptors in cells of the immune system. Scand J Rheumatol 2004; (Suppl 119): 9-11.
184. Papadopoulos IA, Georgiou PE, Katsimbri PP, Drosos AA. Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study. Clin Rheumatol 2000; 19(1): 6-8.
185. Haus U, Varga B, Stratz T, Späth M, Müller W. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol 2000; (Suppl 113): 55-8.
186. Stratz T, Schochat T, Hrycaj P, et al. Therapy of generalized tendomyopathy (fibromyalgia) caused by blocking 5-HT3 receptors. Z Rheumatol 1994; 53(6): 335-8.
187. Färber L, Stratz TH, Bruckle W, et al. German Fibromyalgia Study Group. Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients. Int J Clin Pharmacol Res 2001; 21(1): 1-13.
188. Stratz T, Fäber L, Varga B, Baumgartner C, Haus U, Müller W. Fibromyalgia treatment with intravenous tropisetron administration. Drugs Exp Clin Res 2001; 27(3): 113-8.
189. Stratz T, Müller W. The use of 5-HT3 receptor antagonists in various rheumatic diseases - a clue to the mechanism of action of these agents in fibromyalgia? Scand J Rheumatol 2000; (Suppl 113): 66-71.
190. Stratz T, Varga B, Müller W. Treatment of tendopathies with tropisetron. Rheumatol Int 2002; 22(6): 219-21.
191. Stratz T, Müller W. Local treatment of rheumatic diseases with the 5-HT3 receptor antagonist tropisetron. Schmerz 2003; 17(3): 2003.
192. Samborski W, Stratz T, Mackiewicz S, Müller W. Intra-articular treatment of arthritides and activated osteoarthritis with the 5-HT3 receptor antagonist tropisetron. A double-blind study compared with methylprednisolone. Scand J Rheumatol 2004; (Suppl 119): 51-4.